




## CHEMISCREEN™ MEMBRANE PREPARATION RECOMBINANT HUMAN CB<sub>2</sub> CANNABINOID RECEPTOR


<b>CATALOG NUMBER:</b>	HTS020M	<b>QUANTITY:</b>	200 units
<b>LOT NUMBER:</b>	SC20170620	<b>VOLUME/CONCENTRATION</b>	1 mL, 2 mg/mL

**BACKGROUND:** Cannabinoid compounds include exogenous drugs such as  $\Delta^9$ -THC, the main psychoactive component of the plant *Cannabis sativa*, and endogenous mediators, such as anandamide, that belong to eicosanoid family. The biological effects of cannabinoids are mediated by a family of two G<sub>i</sub>-coupled 7-transmembrane receptors, CB<sub>1</sub> and CB<sub>2</sub>. The CB<sub>1</sub> receptor is found primarily in brain and mediates the psychoactive effects of cannabinoid ligands. The CB<sub>2</sub> receptor is expressed mainly in immune cells, including mast cells and CD40-activated B cells, where it mediates proliferation and inhibition of migration (Howlett *et al.*, 2002). Activation of CB<sub>2</sub> inhibits the development of liver fibrosis (Julien *et al.*, 2005). In bone, CB<sub>2</sub> is expressed in both osteoblasts and osteoclasts, and functions to prevent bone loss (Ofek *et al.*, 2006). In addition, activation of CB<sub>2</sub> has an antinociceptive effect in animal models of neuropathic, inflammatory, and acute pain; this effect is mediated by release of endogenous opioids in the periphery (Ibrahim *et al.*, 2005). CB<sub>2</sub> membrane preparations are crude membrane preparations made from stable recombinant cell lines with a high-level of GPCR surface expression; thus, they are ideal HTS tools for screening for agonists and antagonists of CB<sub>2</sub>.


**APPLICATIONS:** Radioligand Binding Assay



**Figure 1. Saturation binding for CB<sub>2</sub>.** 5  $\mu$ g/well CB<sub>2</sub> Membrane Preparation was incubated with increasing amount of <sup>3</sup>H-labeled CP55,940 in the absence (total binding, TB) or presence (nonspecific binding, NSB) of 1000-fold excess unlabeled CP55,940. Specific binding (SB) was determined by subtracting NSB from TB. Sample data from a representative lot.



**Figure 2. Competition binding for CB<sub>2</sub>.** CB<sub>2</sub> Membrane Preparation (5 µg/well) or Chem-1 wild-type Membrane Preparation (cat. # HTS000MC1) was incubated with 2.5 nM <sup>3</sup>H-labeled CP55,940 and increasing concentrations of unlabeled CP55,940. More than 9- fold signal:background was obtained with CB<sub>2</sub> Membrane Preparation at 5 µg/well. Representative sample data.



**Figure 3. Binding of [<sup>35</sup>S]-GTP<sub>γ</sub>S to CB<sub>2</sub> membrane preparation.** 5 µg/well CB<sub>2</sub> Membrane Preparation (catalog # HTS020M2) and Wild-type Chem-1 Membrane Preparation (catalog # HTS000MC1) were incubated with 0.3 nM [<sup>35</sup>S]-GTP<sub>γ</sub>S, 10 µM GDP, and increasing amounts of unlabeled CP-55940. Bound radioactivity was determined by filtration and scintillation counting. The data are from a representative lot.



**SPECIFICATIONS: Radioligand Binding:**

1 unit = 5 µg  
B<sub>max</sub>: 16.14 pmol/mg  
K<sub>d</sub>: 2.5 nM  
Signal:background: >9-fold

**GTPγS Assay:**

1 unit = 5 µg  
EC50: 2.5 pmol/mg

Species: Human CB<sub>2</sub> (Accession number X74328)

HOST CELLS: Chem-4, an adherent cell line expressing the promiscuous G-proteins.

RECOMMENDED ASSAY CONDITIONS: Membranes are mixed with radioactive ligand and unlabeled competitor (see Figures 1 and 2 for concentrations tested) in binding buffer in a nonbinding 96-well plate, and incubated for 1-2 h. Prior to filtration, an FC 96-well harvest plate (EMD Millipore cat. # MAHF C1H) is coated with 0.33% polyethyleneimine for 30 min, then washed with 50 mM HEPES, pH 7.4, 0.5% BSA. Binding reaction is transferred to the filter plate, and washed 3 times (1 mL per well per wash) with Wash Buffer. The plate is dried and counted.

Binding Buffer: 50 mM Hepes, pH 7.4, 5 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 0.2% BSA, filtered and stored at 4°C

Radioligand: [<sup>3</sup>H]-CP55,940 (Perkin Elmer #NET1051)

Wash Buffer: 50 mM Hepes, pH 7.4, 500 mM NaCl, 0.1% BSA, filtered and stored at 4°C.

One package contains enough membranes for at least 200 assays (units), where a unit is the amount of membrane that will yield greater than 9-fold signal:background with <sup>3</sup>H-labeled CP55,940 at 2.5 nM.

**PRESENTATION:**

Liquid in packaging buffer: 50 mM Tris pH 7.4, 10% glycerol, and 1% BSA with no preservatives. Packaging method: Membrane proteins were adjusted to the indicated concentration in packaging buffer, rapidly frozen, and stored at -80°C.

**STORAGE/HANDLING:**

Store at -70°C. Product is stable for at least 6 months from the date of receipt when stored as directed. Avoid repeated freeze/thaw cycles.

**REFERENCE:**

1. Howlett AC *et al.* (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol. Rev.* 54: 161-202.
2. Ibrahim MM *et al.* (2005) CB<sub>2</sub> cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. *Proc. Natl. Acad. Sci. USA* 102: 3093-8.
3. Julien B *et al.* (2005) Antifibrogenic role of the cannabinoid receptor CB<sub>2</sub> in the liver. *Gastroenterology* 128: 742-755.
4. Ofek O *et al.* (2006) Peripheral cannabinoid receptor, CB<sub>2</sub>, regulates bone mass. *Proc. Natl.*



*Acad. Sci. USA 103: 696-701.*

**Important Note:** *During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For products with volumes of 200  $\mu$ L or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container's cap.*

FOR RESEARCH USE ONLY; NOT FOR USE IN DIAGNOSTIC  
PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

©2006 - 2013: Merck KGaA, Darmstadt. All rights reserved. No part of these works may be reproduced in any form without permission in writing.